Literature DB >> 11803567

Transglutaminase factor XIIIA in the cartilage of developing avian long bones.

M V Nurminskaya1, B Recheis, J Nimpf, Cordula Magee, T F Linsenmayer.   

Abstract

Previously, we showed that mRNA for transglutaminase factor XIIIA (FXIIIA) is up-regulated in the hypertrophic zone of the growth plate of the chicken tibiotarsus, a well-characterized model of long bone development. In the present study, we have studied the distribution of the FXIIIA protein and of transglutaminase enzymatic activity in this growth plate, as well as in the cartilage of the epiphysis, which includes that of the articular surface. By immunohistochemical analysis, the protein is detected in the zone of maturation, where it is mostly intracellular, and in the hypertrophic zone, where it is present both intracellularly and in the extracellular matrix. The intracellular enzyme is mostly a zymogen, as determined with an antibody specific for the activation peptide. Externalization of FXIIIA is accompanied by enzyme activation. To study the pattern of transglutaminase activity, a synthetic transglutaminase substrate, rhodamine-conjugated tetrapeptide (Pro-Val-Lys-Gly), was used for pulse labeling in organ cultures. Intensive incorporation of the fluorescent substrate was observed throughout the hypertrophic zone and in the cells surrounding the forming blood vessels. The patterns of FXIIIA immunostaining and substrate incorporation overlap almost completely. The cartilaginous factor XIIIA is different from the plasma form in that, both intracellularly and extracellularly, it exists as a monomer, as determined by Western analysis, whereas the plasma form of FXIII is a tetrameric complex composed of both A and B subunits. We also identified FXIIIA and transglutaminase activity within the articular and condylar regions of the tarsus, suggesting a possible involvement of mechanical pressure and/or stress in the production of the molecule and subsequent cross-linking of the cartilage matrix. Thus, transglutaminases, in particular FXIIIA, are involved in the formation of long bones through its activity both in the hypertrophic region of the growth plate and in the formation of articular/epiphyseal cartilages. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803567     DOI: 10.1002/dvdy.1230

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  6 in total

Review 1.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

2.  Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification.

Authors:  Kelly E Beazley; Stephanie Deasey; Florence Lima; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

3.  Characterization of the transglutaminase gene family in zebrafish and in vivo analysis of transglutaminase-dependent bone mineralization.

Authors:  Stephanie Deasey; Olga Grichenko; Shaojun Du; Maria Nurminskaya
Journal:  Amino Acids       Date:  2011-08-02       Impact factor: 3.520

4.  Regulation of gene expression by PI3K in mouse growth plate chondrocytes.

Authors:  Veronica Ulici; Claudine G James; Katie D Hoenselaar; Frank Beier
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

5.  Factor XIIIA mobilizes transglutaminase 2 to induce chondrocyte hypertrophic differentiation.

Authors:  Kristen A Johnson; David M Rose; Robert A Terkeltaub
Journal:  J Cell Sci       Date:  2008-06-10       Impact factor: 5.285

6.  Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics.

Authors:  Hadil F Al-Jallad; Vamsee D Myneni; Sarah A Piercy-Kotb; Nicolas Chabot; Amina Mulani; Jeffrey W Keillor; Mari T Kaartinen
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.